Management of digital ulcers in patients with systemic sclerosis;Digitale Ulzera bei systemischer Sklerose: Diagnostik und Therapie

Deutsche Medizinische Wochenschrift

Volumn 137, Issue 1-2, 2012, Pages 34-40

  Riemekasten, G ^a   Hoffmann, U ^b   Sunderktter, C ^c   Weiss, N ^d   Kuhn, A ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

bosentan; digital ulcers; endothelin receptor antagonist; iloprost; systemic sclerosis; therapy

Indexed keywords

ARTICLE; DIGITAL ULCER; SYSTEMIC SCLEROSIS; ULCER;

ANTIHYPERTENSIVE AGENTS; FEMALE; FINGERS; HUMANS; ILOPROST; ISCHEMIA; MALE; RAYNAUD DISEASE; RECEPTORS, ENDOTHELIN; RISK FACTORS; SCLERODERMA, SYSTEMIC; SKIN ULCER; SULFONAMIDES; VASODILATOR AGENTS;

EID: 83755170532     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0031-1298798     Document Type: Article

References (30)

1. Abou-Raya A, Abou-Raya S, Helmii M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. J Rheumatol: 2008; 35 1801 1808
2. Brckner C, Becker MO, Kroenck T et al. Effect of Sildenafil on digital ulcers in systemic sclerosis analysis from a single centre pilot study. Ann Rheum Dis: 2009; 60 835 843
3. Christopeit M, Schendel M, Fll J et al. Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L. Leukemia: 2008; 22 1062 1604
4. Deutsches Netzwerk für systemische Sklerodermie (DNSS); Stand 8/2007; http://www.sklerodermie.info/dnsscontent/m1/k5/index.aspxx
5. Distler O, Gay S. Sklerodermie. Internist: 2010; 51 30 38
6. Fiori G, Galluccio F, Braschi F et al. Vitamin E gel reduces time of healing of digital ulcers in systemic sclerosis. Clin Exp Rheumatol: 2009; 27 51 54
7. Fries R, Shariat K, von Wilmowsky H et al. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation: 2005; 112 2980 2985 (Pubitemid 41612301)
8. Kawald A, Burmester GR, Huscher D et al. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study. J Rheumatol: 2008; 35 1830 1837
9. Korn JH, Mayes M, Matucci CerinicM et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum: 2004; 12; 3985 3993
10. Kowal-Bielecka O, Landew R, Avouac J et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis: 2009; 68 620 628
11. Kuhn A, Haust M, Ruland V et al. Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial. Rheumatology (Oxford): 2010; 49 1336 1345
12. Matucci-Cerinic M, Denton CP, Furst DE et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis: 2011; 70 32 38
13. Milanetti F, Bucha J, Testori A et al. Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis. Curr Stem Cell Res Ther: 2010; Oct 18. [Epub ahead of print]
14. Milburn PB, Singer JZ, Milburn MA. Treatment of scleroderma skin ulcers with a hydrocolloid membrane. J Am Acad Dermatol: 1989; 21 (2 Pt 1) 200 204 (Pubitemid 19195879)
15. Mouthon L, Mestre-Stanislas C, Brezn A et al. Impact of digital ulcers on disability and health-related quality of life in systemic sclerosis. Ann Rheum Dis: 2010; 69 214 217
16. Mller-Ladner U. Akrale Ischmiesyndrome: vom Raynaud-Syndrom zur systemischen Sklerose. Bremen/London/Boston UNI-MED Verlag AG: 2009
17. Ozgocmen S, Kaya A, Coskun BK. Topical lidocaine helps reduce pain of digital ulcers in systemic sclerosis (scleroderma). Clin Rheumatol: 2006; 25 378 379
18. Pope J, Fenlon D, Thompson A et al. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev.: 2000; 02 CD000953
19. Rademaker M, Cooke ED, Almond NE et al. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. BMJ: 1989; 4 561 564 (Pubitemid 19072096)
20. Rosato E, Borghese F, Pisarri S et al. The treatment with N-acetylcysteine of Raynaud's phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients. Clin Rheumatol: 2009; 28 1379 1384
21. Scherer HU, Burmester GR, Riemekasten G. Targeting activated T cells: successful use of anti-CD25 monoclonal antibody basiliximab in a patient with systemic sclerosis. Ann Rheum Dis: 2006; 65 1245 1247 (Pubitemid 44277408)
22. Scorza R, Caronni M, Mascagni B et al. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study. Clin Exp Rheumatol: 2001; 19 503 508 (Pubitemid 32894599)
23. Sebastiani M, Manfredi A, Colaci M et al. Capillaroscopic skin ulcer risk index: a new prognostic tool for digital skin ulcer development in systemic sclerosis patients. Arthritis Rheum: 2009; 61 688 694
24. Shenoy PD, Kumar S, Jha LK et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology Oxford: 2010; 49 2420 2428
25. Steen V, Denton CP, Pope JE et al. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford): 2009; 48 03 iii19 24
26. Sunderktter C, Riemekasten G. Raynaud-Phnomen in der Dermatologie. Teil 2: Therapie. Hautarzt: 2006; 57 927 938
27. Sunderktter C, Herrgott I, Brckner C et al. Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. Br J Dermatol: 2009; 160 835 843
28. Wigley FM, Wise RA, Seibold JR et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med: 1994; 120 199 206
29. Wigley FM, Seibold JR, Wise RA et al. Intravenous iloprost treatment of Raynauds phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol: 1992; 19 1407 1414
30. Yoon J, Giacopelli J, Granoff D et al. Treatment of scleroderma skin ulcers using becaplermin gel and hydrocolloid membrane. J Am Podiatr Med Assoc: 2002; 92 350 354 (Pubitemid 44140557)